Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Review, H2 2015 Is Released

it Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015 Summary Global Markets Direct s, Attention
Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015, provides an overview of the Attention
Deficit Hyperactivity Disorder (ADHD)s therapeutic pipeline. This report provides comprehensive
information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD),
complete with comparative analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates,
and featured news and press releases. It also reviews key players involved in the therapeutic
development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and
discontinued projects. Global Markets Directs report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and
information sourced from Global Markets Directs proprietary databases, Company/University websites,
SEC filings, investor presentations and featured press releases from company/university sites and
industry-specific third party sources, put together by Global Markets Direct s team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of
processes that ensures that all the profiles are updated with the latest set of information. Additionally,
processes including live news & deals tracking, browser based alert-box and clinical trials registries
tracking ensure that the most recent developments are captured on a real time basis. The report
enhances decision making capabilities and help to create effective counter strategies to gain
competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered
based on the availability and relevance of data for the indicated disease. Scope - The report provides a
snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD) - The
report reviews key pipeline products under drug profile section which includes, product description,
MoA and R&D brief, licensing and collaboration details & other developmental activities - The report
reviews key players involved in the therapeutics development for Attention Deficit Hyperactivity
Disorder (ADHD) and enlists all their major and minor projects - The report summarizes all the dormant
and discontinued pipeline projects - A review of the Attention Deficit Hyperactivity Disorder (ADHD)
products under development by companies and universities/research institutes based on information
derived from company and industry-specific sources - Pipeline products coverage based on various
stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed
assessment of monotherapy and combination therapy pipeline projects - Coverage of the Attention
Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of target, MoA, route of administration and
molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides
strategically significant competitor information, analysis, and insights to formulate effective R&D
development strategies - Identify emerging players with potentially strong product portfolio and create
effective counter-strategies to gain competitive advantage - Develop strategic initiatives by
understanding the focus areas of leading companies - Identify and understand important and diverse
types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Plan
mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise
corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder
1

(ADHD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and
expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from pipeline.
with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173369/attentiondeficit-hyperactivity-disorder-adhd-pipeline-review-h2-2015

Browse

To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173369/attention-deficit-hyperactivity-disorder-adhd-pipeline-review-h2-2015

Table of Contents

Introduction 7
Global Markets Direct Report Coverage 7
Attention Deficit Hyperactivity Disorder (ADHD) Overview 8
Therapeutics Development 9
Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview 9
Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis 10
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies 11
Attention Deficit Hyperactivity
Universities/Institutes 15

Disorder

(ADHD)

Therapeutics

under

Investigation

by

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance 16

Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies 20
Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes
24
Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development 25
Alcobra Ltd 25
Amarantus Bioscience Holdings, Inc. 26
APeT Holding BV 27
2

Arbor Pharmaceuticals, LLC. 28

BCWorld Pharm Co. Ltd. 29
Collegium Pharmaceutical, Inc. 30
Curemark, LLC 31
Domain Therapeutics SA 32
DURECT Corporation 33
H. Lundbeck A/S 34
Heptares Therapeutics Limited 35
Highland Therapeutics, Inc. 36
Hisamitsu Pharmaceutical Co., Inc. 37
Integrative Research Laboratories Sweden AB 38
Intra-Cellular Therapies, Inc. 39
KemPharm, Inc. 40
Luc Therapeutics, Inc. 41
Medgenics Inc. 42
Merck & Co., Inc. 43
Neos Therapeutics, Inc. 44
NeuroDerm Ltd. 45
Neurovance, Inc. 46
P2D Bioscience 47
Polleo Pharma Limited 48
Reviva Pharmaceuticals Inc. 49
Samyang Biopharmaceuticals Corporation 50
Shire Plc 51
Signature Therapeutics, Inc 52
Sunovion Pharmaceuticals Inc. 53

Supernus Pharmaceuticals, Inc. 54

Taisho Pharmaceutical Holdings Co., Ltd. 55
Tris Pharma, Inc. 56
Vernalis Plc 57
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Combination Products 59
Assessment by Target 60
Assessment by Mechanism of Action 63
Assessment by Route of Administration 65
Assessment by Molecule Type 67
Drug Profiles 69
(nicotine + opipramol hydrochloride) - Drug Profile 69
amfetamine XR - Drug Profile 70
AR-08 - Drug Profile 71
BCWPE-003 - Drug Profile 72
BLI-1008 - Drug Profile 73
BNC-375 - Drug Profile 74
CB-8411 - Drug Profile 75
centanafadine IR - Drug Profile 76
centanafadine SR - Drug Profile 77
CM-4612 - Drug Profile 78
CTX-1301 - Drug Profile 79
CTX-1302 - Drug Profile 80
dasotraline - Drug Profile 81
dextroamphetamine - Drug Profile 83
dextroamphetamine MR - Drug Profile 84
4

eltoprazine - Drug Profile 85

etiguanfacine - Drug Profile 87
guanfacine hydrochloride ER - Drug Profile 88
histamine dihydrochloride - Drug Profile 90
HTL-1071 - Drug Profile 91
IRL-752 - Drug Profile 92
ITI-214 - Drug Profile 93
KP-415 CR - Drug Profile 94
lisdexamfetamine dimesylate - Drug Profile 96
Metadoxine ER - Drug Profile 100
methylphenidate hydrochloride - Drug Profile 102
methylphenidate hydrochloride - Drug Profile 103
methylphenidate hydrochloride MR - Drug Profile 104
methylphenidate hydrochloride SR - Drug Profile 106
methylphenidate hydrochloride XR - Drug Profile 107
MGS-0028 - Drug Profile 108
molindone hydrochloride ER - Drug Profile 109
NFC-1 - Drug Profile 110
niacinamide CR - Drug Profile 111
NT-0201 - Drug Profile 112
P-001 - Drug Profile 113
PBF-509 - Drug Profile 114
PD-2005 - Drug Profile 116
PD-2007 - Drug Profile 117
PFR-08001 - Drug Profile 118
PFR-8026 - Drug Profile 119

RP-5063 - Drug Profile 120

SHP-465 - Drug Profile 121
Small Molecules for Attention Deficit Hyperactivity Disorder - Drug Profile 122
Small Molecules to Agonize GPR88 for Attention Deficit Hyperactivity Disorder and Schizophrenia - Drug
Profile 123
Small Molecules to Agonize NMDA2D for ADHD - Drug Profile 124
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 125
Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD - Drug Profile 126
Small Molecules to Modulate Choline Transporter for ADHD - Drug Profile 127
TRI-102 - Drug Profile 128
V-81444 - Drug Profile 129
viloxazine hydrochloride - Drug Profile 130
vortioxetine hydrobromide - Drug Profile 131
VU-0238429 - Drug Profile 134
Attention Deficit Hyperactivity Disorder (ADHD) - Recent Pipeline Updates 135
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects 170
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products 175
Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones 176
Featured News & Press Releases 176
Appendix 183
Methodology 183
Coverage 183
Secondary Research 183
Primary Research 183
Expert Panel Validation 183
Contact Us 183
Disclaimer 184

Read More
http://www.idatainsights.com/reports-landing-page.php?id=173369/attention-deficithyperactivity-disorder-adhd-pipeline-review-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects